Efficacy and Safety of Azelaic Acid and Azelaic Acid Combined with Compound Acid in the Treatment of Post-Inflammatory Erythema and Pigmentation of Acne: A Single-center, Prospective, Randomized Controlled Clinical Study Protocol

开始日期2025-02-28

申办/合作机构-

ChiCTR2400091074

/ RecruitingN/AIIT

Clinical observation of the efficacy and safety of azelaic acid combined with alpha hydroxy acid and alpha hydroxy acid in the treatment of melasma

开始日期2024-10-21

申办/合作机构-

100 项与壬二酸相关的临床结果

登录后查看更多信息

100 项与壬二酸相关的转化医学

登录后查看更多信息

100 项与壬二酸相关的专利（医药）

登录后查看更多信息

5,899

项与壬二酸相关的文献（医药）

2025-12-31·CyTA-Journal of Food

Phytochemical composition, phytotoxicity, and ADME modeling of Artemisia absinthium L.: implications for food safety and pharmaceutical applications

作者: Benali, Mohammed ; Gharibi, Elkhadir ; Mothana, Ramzi A. ; Ed-darraz, Fatima-Zahrae ; Bouyanzer, Abdelhamid ; Farihi, Ayoub ; Hawwal, Mohammed F. ; Hbika, Asmae

Artemisia absinthium, an aromatic herb distinguished by its characteristic bitter flavor, has been used in a variety of culinary applications.This study investigates its metabolites through phytochem. methods.The primary minerals in Artemisia absinthium stems are potassium (41%) and calcium (38.3%), forming most of its mineral content.The ethanolic extract exhibited the highest phenolic compound content, with 37.6 ± 0.09 mg GAE/g DE.The primary volatile compound identified was β-thujone, comprising over 26.6% of the volatile content.Palmitic acid is the predominant fatty acid in the hexanic extract (18.7%), while linoleic acid is the main fatty acid in the Et acetate extract (42.4%).Twenty phenolic compounds were identified, with 8-methoxyflavone, (+)-catechin hydrate, and chlorogenic acid as major compounds in dichloromethane, Et acetate, and ethanol extracts, resp.ADME modeling indicating that 8-methoxyflavone, a major component in the dichloromethane extract, is a promising candidate for drug development targeting the central nervous system.

2025-08-01·FOOD CHEMISTRY

Utilizing UHPLC-HRMS-metabolomic profiling to uncover enhanced bioactive potential and health benefits in chili (Capsicum annum L.) under salinity stress

Article

作者: Choudhary, Krishna Kumar ; Singh, Amantika

The modern emphasis on food quality, nutritional value, and health benefits has increased demand for nutrient-rich foods. Incorporating functional foods with enhanced nutritional profiles into diets is becoming a key strategy in addressing chronic and acute diseases. In this study, a pot experiment was conducted on the 'Kashi Ratna' cultivar of Capsicum annuum L. under salinity levels of 50 and 100 mM as compared to control (0 mM). UHPLC-HRMS untargeted quantitative metabolomic profiling revealed a significant increase in bioactive compounds such as amino acids, vitamins, fatty acids, alkaloids, capsaicinoids, terpenoids and phenolics under salinity stress. While 50 mM led to higher accumulation of metabolites, but the overall impact of 100 mM salinity was higher, affecting more metabolites. Our findings highlight the potential for utilizing salinity-affected lands as a sustainable and cost-effective solution for enhancing nutritional quality of foods particularly in the context of Global Climate Change.

2025-08-01·TALANTA

Characterisation of laser-ablated craters of different painting materials and evaluation with modified LA-APCI-MS system

Article

作者: Lungevics, Janis ; Lohmus, Rynno ; Treshchalov, Alexey ; Hiiop, Hilkka ; Leissoo, Martin ; Arju, Georg ; Vahur, Signe ; Teearu, Anu

The cultural heritage materials (CH) are the most difficult to analyse as they are complex, aged multicomponent mixtures. For the analysis of the composition of organic substances, chromatographic and mass spectrometric (MS) techniques are preferred, but they usually require a small sample piece from the object (risking damaging the artefacts) and additional sample preparation. We have developed a novel flexible laser ablation (LA) coupled to the atmospheric pressure chemical ionisation-MS (LA-APCI-MS) method that could analyse solid organic material directly on the object under atmospheric conditions without removal of the sample piece and sample preparation with minimal visual damage to the surface. The main aim of this work was to investigate the performance of LA-APCI-MS by analysing the pulsed 355 nm Nd:YAG laser's impact on hand-made painting materials (oil and acrylic paints and varnish) by characterising the area and volume of laser-ablated craters (measured with an optical microscope and 3D profilometer) obtained with different laser energies and the number of pulses at 90°, 70°, and 45° incidence angles and evaluating the corresponding MS signals obtained with APCI-MS. The areas of the craters of all the samples obtained with different laser energies and a number of laser pulses at 90°, 70°, and 45° incidence angles were between 4.1·10⁴ to 4.2·10⁵ μm² and volumes 6.9·10⁴ to 4.3·10⁶ μm³. From a cultural heritage perspective, these craters were visually barely noticeable. For analysed materials, the optimal laser pulse fluence (energy density) for achieving maximum MS signals ranged from 1.8 to 2.7 J/cm².

项与壬二酸相关的新闻（医药）

2025-03-06

·vynetherapeutics.com

VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 VYN202 Phase 1b psoriasis trial initiated with results anticipated by year-end 2025 Expected cash runway into 2H 2026 BRIDGEWATER, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the fourth quarter and year ended December 31, 2024, and provided a business update. “Based on our significant progress in 2024, we are now positioned to announce two key data readouts for repibresib gel and VYN202 in 2025,” said David Domzalski, President and Chief Executive Officer of VYNE. “We are off to a strong start in 2025. In January, we announced the completion of enrollment in the Phase 2b trial of our locally administered pan-BD BET inhibitor, repibresib, in nonsegmental vitiligo, and we expect to report topline results in mid-2025. We also recently initiated the Phase 1b trial of our oral BD2-selective BET inhibitor, VYN202, in subjects with moderate-to-severe plaque psoriasis, and we anticipate reporting topline results from this trial by the end of this year.” Recent Pipeline Updates Repibresib gel (VYN201), a locally-administered small molecule pan-BD BET inhibitor (Phase 2b, nonsegmental vitiligo): Top-line results from the Phase 2b trial are expected in mid-2025. The fully enrolled, Phase 2b trial (NCT06493578) is a randomized, double-blind, vehicle-controlled trial evaluating the efficacy, safety and pharmacokinetics of once-daily repibresib gel in three dose cohorts (1%, 2% or 3% concentrations) compared to vehicle for 24 weeks in subjects with active or stable nonsegmental vitiligo. Subjects have been randomized equally (1:1:1:1 ratio) across the active drug cohorts or vehicle (approximately 45 subjects in each arm). Top-line results from the 24-week double-blind, vehicle-controlled portion of the trial are expected mid-year. Following the 24-week treatment period, subjects who have been randomized in the three active dose cohorts will continue treatment with their respective dose concentrations for an additional 28-week active treatment extension. Subjects who have been randomized in the vehicle group during the initial 24-week treatment period will be equally re-randomized into one of the three active dose cohorts for an additional 28 weeks. VYN202, an oral small molecule BD2-selective inhibitor: Top-line results from the Phase 1b trial are expected by year-end 2025. In February 2025, the Company announced the initiation of patient enrollment in the Phase 1b trial which is a randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability and pharmacokinetics of once-daily VYN202 in three dosing cohorts (0.25 mg, 0.5 mg, 1 mg doses) compared to placebo, for 12 weeks in subjects with moderate-to-severe plaque psoriasis. Exploratory efficacy of VYN202 will also be evaluated, including measures of psoriasis area and severity index, Static Physician Global Assessment, scalp disease, quality of life, and biomarker analyses. Subjects will be randomized equally (1:1:1:1, approximately 20 subjects per arm) across the active drug cohorts or placebo. Following the 12-week treatment period, all subjects will be followed for a 4-week safety period. Upcoming Conference Participation Investor Conferences. VYNE will be participating in the upcoming Leerink Partners Global Healthcare Conference, taking place in Miami from March 10-12, 2025, as well as the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference being held on March 27, 2025. Financial Results as of and for the Year Ended December 31, 2024 Cash position. As of December 31, 2024, VYNE had $61.5 million of cash, cash equivalents and marketable securities. Based on current operating assumptions, VYNE believes its cash, cash equivalents and marketable securities as of December 31, 2024 will be sufficient to fund its operations into the second half of 2026. Share count. As of December 31, 2024, VYNE had 14,830,013 common shares issued and outstanding, and outstanding pre-funded warrants to purchase 27,842,740 shares of common stock at an exercise price of $0.0001 per share. Revenues. Revenues totaled $0.5 million and $0.4 million for the years ended December 31, 2024 and 2023, respectively, consisting of royalty revenue from the Company's royalty agreement with LEO Pharma A/S, to whom VYNE previously licensed the rights to Finacea® foam. Research and development expenses. VYNE’s research and development expenses for the years ended December 31, 2024 and 2023 were $30.9 million and $16.3 million, respectively. The increase was primarily due to an increase of $11.7 million in expenses for repibresib, an increase of $2.5 million in expenses for VYN202 and an increase of $0.8 million of employee-related expenses following the hiring of additional research and development personnel. The $11.7 million increase in expenses for repibresib primarily relates to preparatory activity and clinical trial costs incurred for VYNE's ongoing Phase 2b trial of repibresib in subjects with nonsegmental vitiligo. The $2.5 million increase in expenses for VYN202 is primarily associated with costs incurred for our Phase 1a SAD/MAD trial which was completed in the fourth quarter of 2024. Both trials were initiated in June 2024. These increases were partially offset by lower consulting expenses of $0.4 million. General and administrative expenses. VYNE’s general and administrative expenses for the years ended December 31, 2024 and 2023 were approximately $13.2 million and $13.4 million, respectively. The decrease was primarily driven by a reduction in employee related expenses of $0.9 million, partially offset by increased consulting and professional fees of $0.8 million. Net loss. Net loss and net loss per share for the year ended December 31, 2024 was $39.8 million and $0.93, respectively, compared to a net loss and net loss per share of $28.5 million and $2.78, for the comparable period in 2023. About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. VYNE's unique and proprietary BET inhibitors, which comprise its InhiBET™ platform, are designed to overcome limitations of early generation BET inhibitors by leveraging alternative routes of administration and enhanced selectivity. For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts. Investor Relations:John FrauncesLifeSci Advisors, LLC917-355-2395jfraunces@lifesciadvisors.com Tyler ZerondaVYNE Therapeutics Inc.908-458-9106Tyler.Zeronda@VYNEtx.com Media Relations: Mike BeyerSam Brown Inc.312-961-2502mikebeyer@sambrown.com Cautionary Statement Regarding Forward-Looking Statements This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the clinical development of, and timing for reporting top-line results from trials of, repibresib and VYN202, the impact of the reported top-line results from trials on clinical development, VYNE's participation in upcoming conferences, VYNE’s projected cash runway, and other statements regarding the future expectations, plans and prospects of VYNE. All statements in this press release which are not historical facts are forward-looking statements. Any forward-looking statements are based on VYNE’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: VYNE’s ability to successfully develop its product candidates; the timing of commencement of future preclinical studies and clinical trials; VYNE’s ability to complete and receive favorable results from clinical trials of its product candidates; VYNE’s ability to obtain additional funding, either through equity or debt financing transactions or collaboration arrangements; and VYNE’s ability to comply with various regulations applicable to its business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in VYNE’s Annual Report on Form 10-K for the year ended December 31, 2024, and VYNE’s other filings from time to time with the U.S. Securities and Exchange Commission. Although VYNE believes these forward-looking statements are reasonable, they speak only as of the date of this announcement and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events. Third-party products and company names mentioned herein may be the trademarks of their respective owners.

临床1期临床2期财报

2025-01-09

·生物谷

告别面部痘痘困扰！Int Immunopharmacol｜芳烃受体激活促肥大细胞自噬，开启面部痘痘治疗新路径

宝子们，有没有过这样的经历：精心准备出门约会或参加重要聚会，临出门前对着镜子一看，脸上不知何时冒出了红斑，还有些小丘疹若隐若现，瞬间心情就像坠入了冰窖。又或者在日常工作中，总感觉面部灼热、瘙痒，让人坐立不安，严重影响了生活和社交。其实，这可能就是玫瑰痤疮在作祟。这种慢性炎症性皮肤病，困扰着许多人。传统治疗手段如使用甲硝唑、壬二酸、异维A酸等药物，虽有一定疗效，但往往伴随着诸如皮肤瘙痒、灼烧感、潜在的视网膜病变及致畸风险等副作用。激光疗法虽能缓解红斑症状，但对于丘疹脓疱性病变效果不佳，且费用高昂。近期一项发表在Int Immunopharmacol的研究Activation of aryl hydrocarbon receptor ameliorates degranulation of LL-37 induced mast cells in rosacea through enhancing autophagy为玫瑰痤疮治疗带来了新的希望。研究发现，肥大细胞在玫瑰痤疮的发病过程中起着关键作用。在患者的皮肤病变部位，肥大细胞数量显著增加，这些被激活的肥大细胞会释放出多种细胞因子，如白细胞介素-6（IL-6）、肿瘤坏死因子（TNF-α）、基质金属蛋白酶（MMP9）等，这些细胞因子进一步加剧炎症反应，推动病情发展。在本研究中，科研人员以肥大细胞（RBL-2H3）为研究对象，用LL-37处理模拟玫瑰痤疮环境。随后加入AhR激动剂（tapinarof），并利用自噬激动剂（RAPA）和抑制剂（CQ）探究其机制。研究结果显示，在细胞脱颗粒与炎症因子表达方面，LL-37处理后，肥大细胞内的脱颗粒标记物Cma1和Tpsab1在蛋白和mRNA水平上随时间显著上升，24小时达到高峰，同时炎症因子IL-6、MMP9和TNF-α的mRNA表达也在24小时明显增加。而tapinarof处理24小时后，Cma1和Tpsab1的蛋白及mRNA表达大幅降低，IL-6、MMP9和TNF-α的mRNA表达也显著下降，表明tapinarof能有效抑制肥大细胞脱颗粒及炎症反应。观察自噬标记物变化发现，随着tapinarof浓度增加，Western blot检测发现LC3B-I逐渐向LC3B-II转化，p62含量减少。经Image J软件分析，证实自噬在tapinarof作用下增强。免疫荧光染色显示，tapinarof+LL-37组中LC3B-II点状聚集数量比仅LL-37诱导的肥大细胞明显增多，进一步证明tapinarof促进自噬。在自噬调节剂与tapinarof协同关系方面，对于自噬激动剂RAPA，浓度高于5 μM会降低细胞活力，但5 μ MRAPA与10 μM tapinarof共同作用于16 μM LL-37诱导的肥大细胞24小时或48小时后，Western blot结果显示LC3B-II表达随tapinarof处理时间延长而上升，验证了自噬增强效果。对于自噬抑制剂CQ，浓度高于5 μM显著降低细胞活力，在16 μM LL-37处理24小时的细胞中，先加5 μM CQ处理4小时再用tapinarof处理24小时后，与未加CQ组相比，CQ仅部分抑制tapinarof诱导的自噬，且RT-qPCR分析表明CQ使Cma1、Tpsab1、MMP9、TNF-α和IL-6表达增加，证实自噬在tapinarof缓解炎症中起关键作用，且CQ可逆转tapinarof的部分抗炎效果。图 1. tapinarof减轻肥大细胞中的玫瑰痤疮样炎症图 2. tapinarof诱导自噬以减少肥大细胞中的玫瑰痤疮样炎症反应此前研究已表明AhR激活可改善小鼠玫瑰痤疮样皮疹并抑制相关细胞信号通路，此次研究进一步明确了其通过增强自噬减轻肥大细胞脱颗粒从而缓解玫瑰痤疮的机制。尽管目前该研究仅处于体外实验阶段，但已为玫瑰痤疮的治疗研究指明了新方向。未来还需开展动物及临床研究进一步验证，若能成功转化为临床应用，有望为玫瑰痤疮患者带来更有效、更安全的治疗方案，极大地改善患者的生活质量，推动皮肤病治疗的发展。参考文献： Chen S, Hu H, Wu J, et al. Activation of aryl hydrocarbon receptor ameliorates degranulation of LL-37 induced mast cells in rosacea through enhancing autophagy. Int Immunopharmacol. Published online December 29, 2024. doi:10.1016/j.intimp.2024.113910 本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！点击下方「阅读原文」，前往生物谷官网查询更多生物相关资讯~

信使RNA

2024-11-07

·GlobeNewswire-Health Care

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025Reported positive first-in-human Phase 1a SAD data for VYN202, with MAD data expected in Q4 2024 BRIDGEWATER, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the three and nine months ended September 30, 2024 and provided a business update. “We continue to make excellent progress in advancing our two InhiBET™ clinical programs VYN201 and VYN202, and believe each product candidate has the potential to be a differentiated, class-leading therapy for immune-mediated diseases,” said David Domzalski, President and Chief Executive Officer of VYNE. “We recently reported positive SAD data from our Phase 1a SAD/MAD trial of oral, BD2-selective BET inhibitor, VYN202, and we anticipate reporting data from the MAD portion of the trial later this quarter. We are encouraged by the strong enrollment in our ongoing Phase 2b trial for VYN201 which we believe underscores the significant unmet need in the treatment of vitiligo. We expect to complete enrollment next month and report topline data mid- next year.” Recent Pipeline Updates VYN201, a locally-administered small molecule pan-BD BET inhibitor: Phase 2b trial of VYN201 in nonsegmental vitiligo exceeds initial enrollment target and expected to complete enrollment next month. The Phase 2b trial is expected to be fully enrolled in December 2024, with approximately 40 to 50 subjects per arm. The trial was initiated in June 2024 and VYNE expects to report top-line results from the 24-week double-blind portion of the trial in mid-2025.The Phase 2b trial (NCT06493578) is a randomized, double-blind, vehicle-controlled trial evaluating the efficacy, safety and pharmacokinetics of once-daily VYN201 gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks. Subjects are being randomized equally (1:1:1:1 ratio) across the active drug cohorts or vehicle. Following the 24-week treatment period, subjects who have been randomized in the three dose cohorts will have the option to continue treatment with their respective dose concentrations for an additional 28-week extension. Subjects who have been randomized in the vehicle group during the initial 24-week treatment period will be equally re-randomized into one of the three active dose cohorts for an additional 28 weeks. VYN202, an oral small molecule BD2-selective inhibitor: VYNE expects to report top-line results from the multiple ascending dose (“MAD”) portion of the Phase 1a trial in the fourth quarter of 2024. Data from the single ascending dose (“SAD”) portion of the trial, announced in September 2024, showed that VYN202 was generally well tolerated with no drug related adverse events. Assessment of key pharmacokinetic and pharmacodynamic parameters demonstrated dose dependent drug concentrations of VYN202 in the blood and showed pharmacodynamic impact of VYN202 on key target-engagement and inflammatory biomarkers in whole blood assays, including an inhibitory effect on select inflammatory biomarkers relevant to psoriasis and rheumatoid arthritis.Pending successful completion of the Phase 1a trial, VYNE plans to initiate Phase 1b trials in adult subjects with moderate-to-severe plaque psoriasis and moderate-to-severely active rheumatoid arthritis, with top-line results anticipated in the second half of 2025. Financial Results as of and for the Third Quarter Ended September 30, 2024 Cash position. As of September 30, 2024, VYNE had cash, cash equivalents, restricted cash and marketable securities of $70.2 million. VYNE believes its cash, cash equivalents, restricted cash and marketable securities as of September 30, 2024 will be sufficient to fund its operations through the end of 2025. Share count. As of September 30, 2024, VYNE had 14,751,433 shares issued and outstanding, and outstanding pre-funded warrants to purchase 27,842,740 shares of common stock at an exercise price of $0.0001 per share. Revenues. Revenues totaled $0.1 million for both the quarters ended September 30, 2024 and 2023, respectively, consisting of royalty revenue from the Company's royalty agreement with LEO Pharma, to whom VYNE previously licensed the rights to Finacea® foam. Research and development expenses. VYNE’s research and development expenses for the quarter ended September 30, 2024 were $10.2 million, representing an increase of $6.9 million, or 208.9%, compared to $3.3 million for the quarter ended September 30, 2023. The increase was primarily driven by increased expenses associated with VYNE's ongoing Phase 2b trial of VYN201 in subjects with nonsegmental vitiligo and its ongoing Phase 1a SAD/MAD trial of VYN202 of $5.0 million and $1.7 million, respectively. Both trials were initiated in June 2024. In addition, employee-related expenses increased by $0.3 million following the hiring of additional research and development personnel. General and administrative expenses. VYNE’s general and administrative expenses for both the quarters ended September 30, 2024 and 2023 were approximately $3.0 million, representing an immaterial change year-over-year. Net loss. Net loss and net loss per share for the quarter ended September 30, 2024 were $12.2 million and $0.29, respectively, compared to a net loss and net loss per share of $6.6 million and $2.01, respectively, for the comparable period in 2023. About VYNE Therapeutics Inc. VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. VYNE's unique and proprietary BET inhibitors, which comprise its InhiBET™ platform, are designed to overcome limitations of early generation BET inhibitors by leveraging alternative routes of administration and enhanced selectivity. For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts. Investor Relations:John FrauncesLifeSci Advisors, LLC917-355-2395jfraunces@lifesciadvisors.com Tyler ZerondaVYNE Therapeutics Inc.908-458-9106Tyler.Zeronda@VYNEtx.com Media Relations: Mike BeyerSam Brown Inc.312-961-2502mikebeyer@sambrown.com Cautionary Statement Regarding Forward-Looking Statements This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding VYNE's ability to successfully complete its Phase 1a trial of VYN202, future clinical trials of VYN202, the expected enrollment and timing for reporting top-line results from trials of VYN201 and VYN202, VYNE’s projected cash runway, and other statements regarding the future expectations, plans and prospects of VYNE. All statements in this press release which are not historical facts are forward-looking statements. Any forward-looking statements are based on VYNE’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: VYNE’s ability to successfully develop its product candidates; the timing of commencement of future preclinical studies and clinical trials; VYNE’s ability to complete and receive favorable results from clinical trials of its product candidates; VYNE’s ability to obtain additional funding, either through equity or debt financing transactions or collaboration arrangements; and VYNE’s ability to comply with various regulations applicable to its business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in VYNE’s Annual Report on Form 10-K for the year ended December 31, 2023, and VYNE’s other filings from time to time with the U.S. Securities and Exchange Commission. Although VYNE believes these forward-looking statements are reasonable, they speak only as of the date of this announcement and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events. Third-party products and company names mentioned herein may be the trademarks of their respective owners. VYNE THERAPEUTICS INC.CONDENSED CONSOLIDATED BALANCE SHEETS(U.S. dollars in thousands, except share and per share data)(Unaudited) September 30, December 31, 2024 2023 Assets Current Assets: Cash and cash equivalents$16,272 $30,620 Restricted cash 47 54 Investment in marketable securities 53,913 62,633 Prepaid and other current assets 3,303 2,656 Total Current Assets 73,535 95,963 Non-current Assets: Operating lease right-of-use assets 122 207 Non-current prepaid expenses and other assets 2,541 1,515 Total Non-current Assets 2,663 1,722 Total Assets$76,198 $97,685 Liabilities and Stockholders’ Equity Current Liabilities: Trade payables$3,986 $1,659 Accrued expenses 6,168 4,119 Employee related obligations 1,071 1,645 Operating lease liabilities 123 115 Other current liabilities 1,313 — Total Current Liabilities 12,661 7,538 Long-term Liabilities: Non-current operating lease liabilities — 99 Other liabilities — 1,313 Total Long-term Liabilities — 1,412 Total Liabilities 12,661 8,950 Commitments and Contingencies Stockholders' Equity: Preferred stock: $0.0001 par value; 20,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023 — — Common stock: $0.0001 par value; 150,000,000 shares authorized at September 30, 2024 and December 31, 2023; 14,751,433 and 14,098,888 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 1 1 Additional paid-in capital 782,650 780,044 Accumulated other comprehensive income 34 26 Accumulated deficit (719,148) (691,336)Total Stockholders' Equity 63,537 88,735 Total Liabilities and Stockholders’ Equity$76,198 $97,685 VYNE THERAPEUTICS INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(U.S. dollars in thousands, except per share data)(Unaudited) Three Months EndedSeptember 30, Nine Months EndedSeptember 30, 2024 2023 2024 2023 Revenues Royalty revenues$121 $114 $417 $348 Total Revenues 121 114 417 348 Operating Expenses: Research and development 10,248 3,318 21,262 13,284 General and administrative 2,964 3,030 10,022 9,490 Total Operating Expenses 13,212 6,348 31,284 22,774 Operating Loss (13,091) (6,234) (30,867) (22,426)Other income, net 934 163 3,074 706 Loss from continuing operations before income taxes (12,157) (6,071) (27,793) (21,720)Income tax expense — — — — Loss from continuing operations (12,157) (6,071) (27,793) (21,720)Loss from discontinued operations, net of income taxes — (513) (19) (544)Net Loss$(12,157) $(6,584) $(27,812) $(22,264) Loss per share from continuing operations, basic and diluted$(0.29) $(1.85) $(0.65) $(6.66)Income (loss) per share from discontinued operations, basic and diluted$0.00 $(0.16) $0.00 $(0.17)Loss per share, basic and diluted$(0.29) $(2.01) $(0.65) $(6.82) Weighted average shares outstanding - basic and diluted 42,587 3,282 42,592 3,271

临床2期临床1期财报临床结果

100 项与壬二酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03034	壬二酸	D10AX03	DB00548

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
丘疹性荨麻疹	美国	LEO Pharma A/S	2002-12-24
玫瑰痤疮	美国	LEO Pharma A/S	2002-12-24
炎症	美国	Almirall LLC	1995-09-13
寻常痤疮	韩国	Dongkwang Pharm Co. Ltd.	1994-02-17

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脂溢性皮炎	临床2期	德国	Leo Pharma, Inc.	2006-12-01
口周皮炎	临床2期	德国	Leo Pharma, Inc.	2006-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCD2023	N/A	色素沉着过多	-	azelaic acid (SPF50+ broad-spectrum UVB-UVA-BL sunscreen (light texture))	艱糧網淵鬱鹹鏇範壓鹽(衊觸廠顧蓋餘鹹鏇築積) = markedly detectable by human eye (ΔE=6.5) on UV-pigmented epidermis 衊餘衊築遞淵簾積網醖 (遞蓋齋窪餘窪觸觸範鑰 )	-	2023-07-03
NCT02800148 (CTgov)	临床3期	玫瑰痤疮	667	Azelaic acid foam (Azelaic Acid Foam)	範鑰顧顧網窪鏇衊範鬱(顧鹹選顧積憲鏇廠築願) = 鑰鏇遞繭遞膚壓齋獵願艱構餘選艱膚鹹壓繭餘 (築淵襯網顧鹹淵廠範膚, 33.623) 更多	-	2020-12-09
				Azelaic acid foam (Finacea Foam)	範鑰顧顧網窪鏇衊範鬱(顧鹹選顧積憲鏇廠築願) = 願製鏇選顧衊觸膚觸鑰艱構餘選艱膚鹹壓繭餘 (築淵襯網顧鹹淵廠範膚, 34.513) 更多
NCT02120924 (CTgov)	临床3期	玫瑰痤疮	1,009	Azelaic Acid (Azelaic Acid, 15% Topical Gel)	選淵積選繭憲繭觸願糧(鑰鬱製醖壓鹽選齋願淵) = 築憲憲簾鬱窪遞餘艱顧齋製襯觸醖窪觸遞齋鹹 (顧膚膚網蓋餘餘繭願繭, 29.394) 更多	-	2020-06-02
				Finacea (Finacea® (Azelaic Acid) Gel, 15%)	選淵積選繭憲繭觸願糧(鑰鬱製醖壓鹽選齋願淵) = 窪範願鹽夢簾繭夢齋夢齋製襯觸醖窪觸遞齋鹹 (顧膚膚網蓋餘餘繭願繭, 27.415) 更多
NCT01631656 (CTgov)	N/A	玫瑰痤疮	10	Nd:Yag laser+Azelaic acid (Azelaic Acid Plus Laser)	蓋醖齋襯觸範鑰鹽齋選(製鹹鏇鬱鹽構齋觸醖壓) = 鑰蓋襯蓋鹽願糧膚繭夢獵夢選鏇鹽膚範願鹽顧 (鏇膚願夢壓餘齋窪築顧, 1.2) 更多	-	2017-11-28
				Nd:Yag laser (LASER ONLY)	蓋醖齋襯觸範鑰鹽齋選(製鹹鏇鬱鹽構齋觸醖壓) = 淵獵鹽願壓範鏇憲糧壓獵夢選鏇鹽膚範願鹽顧 (鏇膚願夢壓餘齋窪築顧, 1.4)
NCT02058628 (CTgov)	临床4期	寻常痤疮	222	DUAC (DUAC®)	衊築壓齋蓋選構醖壓製(齋製窪壓夢製襯夢遞鑰) = 繭蓋艱衊選膚蓋構鑰齋願餘築窪遞醖廠構膚齋 (廠壓顧鑰網壓簾鬱鑰廠, 27.6) 更多	-	2017-08-25
				SKINOREN (SKINOREN®)	衊築壓齋蓋選構醖壓製(齋製窪壓夢製襯夢遞鑰) = 鹽鬱衊簾窪餘壓憲窪積願餘築窪遞醖廠構膚齋 (廠壓顧鑰網壓簾鬱鑰廠, 30.9) 更多
NCT02147691 (CTgov)	临床4期	玫瑰痤疮	22	Brimonidine 0.33%	遞顧蓋艱廠衊窪網製衊(襯醖壓範廠簾製齋獵艱) = 築鹽膚窪網膚繭築網鹽艱選窪醖製顧壓範艱鏇 (製齋願衊製蓋憲繭鑰網, 0.3) 更多	-	2015-09-30
NCT01555463 (CTgov)	临床3期	玫瑰痤疮	961	Azelaic acid foam, 15% (BAY39-6251) (Azelaic Acid Foam, 15% (BAY39-6251))	獵衊觸衊衊襯範窪鏇築 = 膚觸憲糧選蓋簾窪選鏇簾憲選願襯簾襯網鑰築 (觸築繭鹽醖築鹽積簾糧, 選鹽鏇糧繭淵窪獵願網 ~ 構繭鬱窪築膚鹹夢遞願) 更多	-	2015-01-27
				Vehicle foam (Vehicle Foam)	獵衊觸衊衊襯範窪鏇築 = 艱鹽簾襯遞選選製糧醖簾憲選願襯簾襯網鑰築 (觸築繭鹽醖築鹽積簾糧, 蓋鑰願淵糧醖鹹窪醖網 ~ 齋窪鏇鹽獵網鹽繭衊蓋) 更多
NCT00617903 (CTgov)	临床2期	玫瑰痤疮	83	Azelaic acid (Azelaic Acid Foam, 15% (BAY39-6251))	選遞淵簾顧憲繭膚繭糧(簾憲憲築觸窪積鹽選艱) = 觸製獵遞廠遞夢製簾範艱鏇鑰壓餘齋鏇糧壓襯 (遞糧衊遞範鹹遞鹽遞憲, 8.53) 更多	-	2013-07-04
				Vehicle foam (Vehicle Foam)	選遞淵簾顧憲繭膚繭糧(簾憲憲築觸窪積鹽選艱) = 醖繭艱夢願齋遞鑰窪餘艱鏇鑰壓餘齋鏇糧壓襯 (遞糧衊遞範鹹遞鹽遞憲, 7.80) 更多
NCT01025635 (CTgov)	临床2期	玫瑰痤疮	401	Azelaic acid foam 15% (Azelaic Acid Foam, 15% (BAY39-6251))	鬱糧蓋簾鑰觸齋窪夢餘 = 積簾憲鬱憲糧築窪簾餘製鏇糧築鑰遞網簾獵衊 (鹽鹹醖選鹽簾廠窪觸夢, 範壓顧齋壓憲願餘夢齋 ~ 襯範餘襯繭壓淵鹽鬱蓋) 更多	-	2013-07-01
				Vehicle foam (Vehicle Foam)	鬱糧蓋簾鑰觸齋窪夢餘 = 繭選餘顧獵衊艱鹹夢膚製鏇糧築鑰遞網簾獵衊 (鹽鹹醖選鹽簾廠窪觸夢, 蓋鏇觸鹹餘齋製遞選範 ~ 積選憲鏇蓋獵蓋獵壓壓) 更多